A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Antibody drug conjugates (ADCs) represent novel anti-cancer modalities engineered to specifically target and kill tumor cells expressing corresponding antigens. Due to their large size and their complex kinetics, these therapeutic agents often face heterogeneous distributions in tumors, leading to large untargeted regions that escape therapy. We present a modeling framework which includes the systemic distribution, vascular permeability, interstitial transport, as well as binding and payload release kinetics of ADC-therapeutic agents in mouse xenografts. We focused, in particular, on receptor dynamics such as endocytic trafficking mechanisms within cancer cells, to simulate their impact on tumor mass shrinkage upon ADC administration. Our model identified undesirable tumor properties that can impair ADC tissue homogeneity, further compromising ADC success, and explored ADC design optimization scenarios to counteract upon such unfavorable intrinsic tumor tissue attributes. We further demonstrated the profound impact of cytotoxic payload release mechanisms and the role of bystander killing effects on tumor shrinkage. This model platform affords a customizable simulation environment which can aid with experimental data interpretation and the design of ADC therapeutic treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the histological architecture of mCRPC—characterized by dense stroma, low vascularity, and high between-tumor heterogeneity—has limited ADC penetration and distribution within tumor tissue219–222.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [221]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Isolation by Size of Epithelial Tumor Cells
Vona, G., Sabile, A., Louha, M., Sitruk, V., Romana, S., Schütze, K., Capron, F., Franco, D., Pazzagli, M., Vekemans, M., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64706-2 · Cited by 1,069
Receptors; models for binding, trafficking and signaling
(1997) · General Pharmacology: The Vascular System · doi:10.1016/s0306-3623(97)90087-2 · Cited by 855
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Antibody–drug conjugates: targeted drug delivery for cancer
Alley, S. C., Okeley, N. M., & Senter, P. D. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.170 · Cited by 656
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions.
Less, J. R., Skalak, T. C., Sevick, E., & Jain, R. K. (1991) · PubMed · Cited by 501
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Endocytosis of Receptor Tyrosine Kinases
Goh, L. K., & Sorkin, A. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a017459 · Cited by 461
Shah, D. K., & Betts, A. M. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9232-2 · Cited by 422
Juweid, M. E., Neumann, R. D., Paik, C. H., Pérez-Bacete, M., Sato, J., van Osdol, W. W., & Weinstein, J. N. (1992) · PubMed · Cited by 406
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365
High-resolution imaging of the dynamic tumor cell–vascular interface in transparent zebrafish
Stoletov, K., Montel, V., Lester, R. D., Gonias, S. L., & Klemke, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703446104 · Cited by 325
Wadleigh, M., Richardson, P. G., Zahrieh, D., Lee, S. J., Cutler, C., Ho, V., Alyea, E. P., Antin, J. H., Stone, R. M., Soiffer, R. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0255 · Cited by 323
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1989) · PubMed · Cited by 299
Shah, D. K., & Betts, A. M. (2013) · mAbs · doi:10.4161/mabs.23684 · Cited by 262
Lin, Y. S., Nguyen, C., Mendoza, J.-L., Escandon, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 255
Specific Growth Rate versus Doubling Time for Quantitative Characterization of Tumor Growth Rate
Mehrara, E., Forssell-Aronsson, E., Ahlman, H., & Bernhardt, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3822 · Cited by 247
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
(2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1171 · Cited by 219
Shah, D. K., Haddish-Berhane, N., & Betts, A. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9276-y · Cited by 160
Hendriks, B. S., Opresko, L. K., Wiley, H. S., & Lauffenburger, D. A. (2003) · PubMed · Cited by 159
Direct in vivo measurement of targeted binding in a human tumor xenograft
Berk, D. A., Yuan, F., Leunig, M., & Jain, R. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1785 · Cited by 145
Baxter, L. T., & Jain, R. K. (1991) · Microvascular Research · doi:10.1016/0026-2862(91)90026-8 · Cited by 144
Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases
Thurber, G. M., Zajic, S. C., & Wittrup, K. D. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037069 · Cited by 141
A Systems Approach for Tumor Pharmacokinetics
Thurber, G. M., & Weissleder, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024696 · Cited by 130
Morphometric analyses of the microvasculature of tumors during growth and after x-irradiation
Hilmas, D. E., & Gillette, E. L. (1974) · Cancer · doi:10.1002/1097-0142(197401)33:1<103::aid-cncr2820330116>3.0.co;2-7 · Cited by 121
Geometric Resistance and Microvascular Network Architecture of Human Colorectal Carcinoma
Less, J. R., Posner, M. C., Skalak, T. C., Wolmark, N., & Jain, R. K. (1997) · Microcirculation · doi:10.3109/10739689709148315 · Cited by 110
Kinetics of binding, endocytosis, and recycling of EGF receptor mutants
Felder, S., LaVin, J., Ullrich, A., & Schlessinger, J. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.117.1.203 · Cited by 109
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
Ackerman, M. E., Pawlowski, D., & Wittrup, K. D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0067 · Cited by 107
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
Gerber, H.-P., Koehn, F. E., & Abraham, R. T. (2013) · Natural Product Reports · doi:10.1039/c3np20113a · Cited by 97
A mathematical model of breast and ovarian cancer treated with paclitaxel
Panetta, J. C. (1997) · Mathematical Biosciences · doi:10.1016/s0025-5564(97)00077-1 · Cited by 94
Waters, C. M., Oberg, K. C., Carpenter, G., & Overholser, K. A. (1990) · Biochemistry · doi:10.1021/bi00466a020 · Cited by 89
HER2-Mediated Effects on EGFR Endosomal Sorting: Analysis of Biophysical Mechanisms
Hendriks, B. S., Wiley, H. S., & Lauffenburger, D. A. (2003) · Biophysical Journal · doi:10.1016/s0006-3495(03)74696-7 · Cited by 63
Vascularization of carcinomas of the esophagus and its correlation with tumor proliferation.
Porschen, R., Classen, S., Piontek, M., & Borchard, F. (1994) · PubMed · Cited by 61
Wiig, H., Gyenge, C. C., & Tenstad, O. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.089615 · Cited by 59
Panetta, J. C., Schaiquevich, P. S., Santana, V. M., & Stewart, C. F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1243 · Cited by 59
Krop, I. E., LoRusso, P. M., Miller, K. D., Modi, S., Yardley, D. A., Rodriguez, G., Agresta, S., Zheng, M., Amler, L. C., & Rugo, H. S. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-5090 · Cited by 46
Chen, R. W., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J. J., Connors, J. M., Engert, A., Larsen, E. K. M., Kennedy, D. A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.8031 · Cited by 41
Comparison of sizes and shapes of tumor cells in plasma cell leukemia and plasma cell myeloma
Isobe, T., Ikeda, Y., & Ohta, H. (1979) · Blood · doi:10.1182/blood.v53.5.1028.1028 · Cited by 15
Research works printed but not linked: 1
- M Dellian, 2000, Vascular permeability in a human tumour xenograft: molecular charge dependence, British Journal of Cancer, 82, 1513
Cited by
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
Sun, X., Ponte, J. F., Yoder, N. C., Laleau, R., Coccia, J., Lanieri, L., Qiu, Q., Wu, R., Hong, E., Bogalhas, M., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00062 · Cited by 277
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., et al. (2017) · Cancer · doi:10.1002/cncr.30789 · Cited by 244
Metadata
- Authors
- Vasalou, C., Helmlinger, G., & Gomes, B.
- Affiliations
- Novartis (United States) (US)
- Corresponding author
- Gomes, Bruce
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-03-18
- Volume
- 10
- Issue
- 3
- Pages
- e0118977
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4364906
- OpenAlex
- W2011733413
- Cited by
- 98
- References
- 49
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 8 · 2018: 9 · 2017: 14 · 2016: 7 · 2015: 3
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- antibody-drug conjugates, tumor penetration, tumor heterogeneity, vascular permeability, interstitial transport, endosomal trafficking, receptor dynamics, bystander killing, tumor shrinkage, xenograft models, pharmacokinetic modeling
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Kinetics, Models, Biological, Neoplasms, Drug Design, Immunoconjugates, Xenograft Model Antitumor Assays, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.